UPDATE 1-BridgeBio Pharma’s heart disease drug meets main goal in late-stage study, Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com

The company said no safety concerns were identified in patients, adding that it intends to submit marketing applications to the US Food and Drug Administration before the end of 2023, with regulatory filings in additional markets to follow in 2024., The company said no safety concerns were identified in patients, adding that it intends to submit marketing applications to the US Food and Drug Administration before the end of 2023, with regulatory filings in additional markets to follow in 2024., , Read More